Posted in:News Fujifilm and Mylan Announce Partnership to Commercialize Adalimumab Biosimilar By Seth Cockrum April 20, 2018 Comments are off Fujifilm Kyowa Kirin Biologics Co., Ltd. (“Fujifilm”) recently announced that it will partner with Mylan N.V. (“Mylan”) to... Read more Tagged with: adalimumab, EMA, Fujifilm Kyowa Kirin, Mylan, News http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News PTAB Institutes Review of AbbVie Patent Directed to Treatment of Chronic Plaque Psoriasis By Seth Cockrum April 19, 2018 Comments are off On the same day that the PTAB instituted review of an AbbVie Biotechnology Ltd. (“AbbVie”) patent covering a method of using adalimumab... Read more Tagged with: AbbVie, adalimumab, News, PTAB, Sandoz http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News PTAB Institutes Review of an AbbVie Patent Directed to Treatment of Psoriatic Arthritis Comprising Administration of Adalimumab By Seth Cockrum April 18, 2018 Comments are off At the urging of Sandoz Inc. (“Sandoz”), the PTAB instituted review of claims 1, 2, and 5-7 of U.S. Patent No. 9,067,992 (“the ʼ992... Read more Tagged with: AbbVie, adalimumab, News, PTAB, Sandoz http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Global Approvals for Insulin Glargine Promise a More Affordable, Long-Acting Treatment for Diabetes By Caitlin M. Wilmot April 3, 2018 Comments are off Last week, Mylan N.V. and Biocon Ltd. announced that their jointly-developed insulin glargine biosimilar, Semglee™, received marketing... Read more Tagged with: Abasaglar™, Biocon, Eli Lilly, FDA, Insulin glargine, Lantus®, Lusduna™, Merck, Mylan, Sanofi, Semglee™, trastuzumab http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Sandoz’s Challenge to Two of AbbVie’s Humira® Patents Denied by PTAB By Monica Chin Kitts February 26, 2018 Comments are off Sandoz’s request for inter partes review (“IPR”) of U.S. Patent Numbers 9,512,216 (“the ’216 patent”) and 8,802,100 (“the... Read more Tagged with: AbbVie, Humira®, IPR, PTAB, Sandoz http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Lupin’s Generic Version of Tamiflu® Joins the Band of Flu Fighters By Caitlin M. Wilmot February 20, 2018 Comments are off Mumbai-based pharmaceutical manufacturer Lupin recently received FDA approval for its generic version of Roche’s Tamiflu® (oseltamivir... Read more Tagged with: FDA, Lupin, oseltamivir phosphate, Roche, Tamiflu® http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Celltrion and Teva File Declaratory Judgment Action Against Thirty-Seven Rituxan®-related Patents By Seth Cockrum January 16, 2018 Comments are off We previously reported that on January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva... Read more Tagged with: Biogen, Celltrion, Genentech, Herceptin®, IPR, News, PTAB, Rituxan®, Rituximab, Roche, Teva, trastuzumab http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus